Progress of clinical pharmacological study on rifabutin

Abstract

Abstract: Rifabutin ( RBT) is a rifamycin deriva- tive, like rifampicin ( RIF) , registered for the prophylaxis and treatment of mycobacterium avium complex ( MAC) in patients with AIDS by FDA in 1992 .Subsequently, the drug was approved by many other countries .But now, it is used not only in the prophlaxis and treatment of mycobac- terium avium complex but also in the treatment of pulmo- nary tuberculosis and Helicobacter pylori .For its high li- pophilic characteristic and weak inducing properties com- pare to other rifamycin derivative, it can be applied in treatment with many diseases successfully, especially when combine with other antibiotics, and can solve the problem of traditional antibiotics resistance and increase the clinical safety of combined medical treatment .This paper just shows the progress of clinical pharmacological study and related aspects on rifabutin in order to instruct prescription .

Key words: Rifabutin ;CYP450 ;drug interaction , MAC;pulmonary tuberculosis ;Helicobacter pylori

CLC Number:

R969

LI Zhao-xu, ZHANG Jin-nan, REN Shuang, GAO Cheng-ying, SUN Yi, WANG Xue. Progress of clinical pharmacological study on rifabutin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(1): 1-9.

References

1 Pretet S, Lebeaut A, Parrot R, Truffot C, Grosset J, Dinhxuan AT.Combined chemotherapy including rifabutin for rifampicin, and isoniazid resistant pulmonary tuberculosis[ J] .Eur Respir J, 1992; 5: 680 -4
2 Brogden RN, Fitton A.Rifabutin a review of its anti-microbial activity, Pharmacokinetic properties and therapeutic efficacy [ J] .Drugs, 1994; 47 : 983-1009
3 Lester W.Rifamycin, a semisynthetic derivative of rifamycin-a prototype of the future[ J] .Annu Rev Microbial, 1972; 26: 85 -102
4 Asghar Q, Sebastian SJ, Thornton L.Rifabutin-and furazolidone- based helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients[ J] . Aliment Pharmcol Ther, 2005; 21 : 91-6
5 Wong WM, Gu Q, Lam SK.Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs quadru- ple therapy as second- line treatment for Helicobacter pylori in- fection[ J] . Aliment Pharmacol Ther, 2003; 17 : 553-60
6 Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM.Rescue therapy with rifabutin after multiple helicobacter py- lori treatment failures[ J] . Helicobacter, 2003; 8 : 90-4
7 Perri F, Festa V, Clemente R.Randomized study of two rescue therapies for helicobacter py lori infected patients after failure of standard triple therapies[ J] . Am J Gastroenterol, 2001; 96: 58 -62
8 Thayer WR.The use of anti-mycobacerial agents in crohn' s Disease[ J] .J Clin Gastroenterol, 1992; 15: 5 -7
9 Wehrli W, Nuesch J, Knusel F, Stachelin M. Action of rifamycins on RNA Polymerase[ J] .Biochim Biophys Acta, 1968; 157: 215 -7
10 Travers AA, Burgess RR. Cyclic RE-Use of the RNA Ploymerase sigma factor[ J] . Nature, 1969;222 : 537 -40
11 Scrutton MC, Wu CW, Goldthwait DA.The presence and possi- ble role of zinc in RNA polymerase obtained from E[ J] .Coli Proc Natl Acad Sci( USA) , 1971; 68 : 2497-501
12 Kono Y. Oxygen enhancement of bacterial activity of rifamy cin SV on E. coli and aerbic oxidation of rifamycin SV to rifamy cin S catalyzed by maganous ions: the role of superoxide[ J] .J Bio- · 6 · Chin J Clin Pharmacol Ther 2006 Jan; 11( 1)chem, 1982 ; 91: 381-95
13 Kono Y, Sugiuhara Y.Electron spin resonace studies on the ox- idation of rifamycin SV catalyzed by the metal irons[ J] .J Bio- chem, 1987 ; 91: 397-401
14 Quinlan GJ, Gutteridge JMC .Oxygen radical damage to DNA by rifamycin SV and copper irons[ J] .Biochem Pharmacol, 1987; 36 : 3629 -33
15 Quinlan GJ, Gutteridge JMC .DNA Base Damage by ? -Lac- tam, Tetracycline, bactitracin and rifamycin antibacteribal anti- biotics[ J] .Biochem Pharmacol, 1991; 42: 1595 -9
16 Hollins PJ, Simmons AV.Jaundice associated with rifamycin [ J] .Tubercle, 1970; 51 : 328-32
17 Lees AW, Ascher B, Hashem M, Sinaha BN.Jaundice after rifamypicin[ J] .Br J Dis Chest, 1971; 64: 90-5
18 Scampini G, Nava A, Newsman AJ, Della-Torre P, Mazue G . Multinucleated hepatocytes induced by rifabutin in rats[ J] . Toxicol Pathol, 1993; 21 : 369-76
19 Hellinger FJ .The lifetime cost of treating a person with HIV [ J] .JAMA, 1993; 270 : 474-8
20 Moore RD, Keruly JC, Chaisson RE .Costs of treating HIV disease under medicaid in maryland[ J] .J Acquir immune Defic Syndr Hum Retrovirol, 1997; 14 : 223-31
21 Gable CB, Tierce JC, Simison D, Ward D, Motte K. Costs of HIV + AIDS at CD4 +counts disease stages based on treatment pro- tocols[ J] . J Acquir Immune Defic Syndr Hum Retrovirol, 1996 ; 12: 413 -20
22 Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Zidovudine Epidemiology Study Group Incidence and natural history of Mycobacterium avium complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine[ J] . Am Rev Respir Dis, 1992; 146: 283 -89
23 Moore RD, Chaisson RE.Natural history of opportunistic diease in an HIV infected urban clinical cohort[ J] . Ann Intern Med, 1996; 124 : 633 -42
24 Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome[ J] . N Engl J Med, 1991 ; 324: 1332 -8
25 Bacellar H, Munoz A, Hoover DR. Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cells cou- nts <100 cells·mm3:Multicenter AIDS cohort study[ J] . J In- fect Dis, 1994; 170: 1284 -7
26 Nightingale SD, Bytrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterum avium-intracellulare complex bactermia in human immunodeficiency virus -positive patients[ J] . J Infect Dis, 1992; 165 : 1082-5
27 Horsburgh CR, Jr Havlik JA, Ellis DA. Survival of patients with acquired immunodeficiency syndrome and disseminated Myco- bactrium avium complex infection with and without antimycobac- terial chemotherapy[ J] . Am Rev Respir Dis, 1991; 144: 557 -9
28 Nightingale SD, Cameron DW, Gordin FM. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS[ J] . N Engi J Med, 1993 ; 329: 828-33
29 Havlir DV, Duble MP, Satter FR . Prophylaxis against dissemi- nated Mycobacterium avium complex with weekly azithromycin , daily rifabutin, or both N Engi[ J] . J Med, 1996; 335 : 392-8
30 Benson CA, Cohn DL, Williams P. For the ACTG 196 CPCRA 009 Study efficacy of clarithromy cin( CLA) vs. rifabutin( RBT) vsCLA +RBT for prevention of Mycobacterim avium complex ( MAC) disease inHIV+ patients with CD4 counts≤100 cells· μ l-1[ R] . ( Abstr. 205) 3rd Conference on Retroviruses and Op- portunistic Infections.Washington, DC, 1996
31 Oldfield EC, Dickinson G, Chung R. Once-weekly azithromy cin for prevention of Mycobacterium avium complex(MAC) infection in AIDS patients[ R] . ( Abstr. 2003) 3rd Conference on Retro- viruses and Opportunisitic infections .Washington DC , 1996
32 谢惠安, 阳国太, 林善祥.现代结核病学[ M] .第一版.北京:人民卫生出版社, 2001 : 510-44
33 钟静, 麦洁儿, 唐惠红.广州市海珠区肺结核病人的耐药性监测[ J] .中国热带医学, 2002; 2 : 390-2
34 Grosset HJ.New approaches in antimycobacterial chemotherapy [ J] .Drugs Today, 1988 ; 24: 291-301
35 Mitchison DA, Ellard GA, Grosset JH .New antimycobacterial drugs for treatment of my cobacterial disease in man[ J] . Br Med Bull, 1988; 44 : 757-74
36 Truffot P, Giroir AM, Majry L, Grosset J.Etude does concentra- tions minimales inhibitrices de rifabutine( Ansamycine LM427) pour Mycobacterium avium-intracelluare[ J] .Rev Mal Respir, 1988 ; 584: 401-6
37 Strolin BM .Efthymiopoulos C, Sassella D, Moro E, Repetto M. Autoinduction of rifabutin metabolism in man[ J] .Xenobiotica, 1990 ; 20: 1113-9
39 Ungheri D, Sanfilippo A. Activity of LM427 on Legionella spp: in vitro study and intracellular killing . In: Ishigami J.Recent ad- vances in chemotherapy[ N] . Tokyo: Univ. Tokyo press, 1986 : pp 1919 -20
38 Mozzi E, Germiniani R, Cantalupi G, Marchetti V, VettaroMP, Sardi A.Human pharmacokinetics of LM427, a new antimyco- bacterial agent : tissue distribution and excretion[ R] .Thirteenth ICC International Congress of chemotherapy Vienna 28August to
2 September. 1983
40 Vander Auwera P, Matsumoto T, Husson M. Intraphagocytic penetration of antibiotics[ J] . J Antimicrob Chemother, 1988 ; 22: 185 -92
41 Perucca E, Grimaldi R, Frigo GM, Sardi A, Monig H, Ohnhaus EE . Comprative effects of rifabutin and rifampicin on hepaticmi- crosomal enzyme activity in normal subjects[ J] .Eur J Clin Pharmacol, 1988; 34: 595 -9
42 Narang PK, Lewis RC, Bianchine JR.Rifabutin absorption in human : relative bioavailability and food effects[ J] . Clin Pharm- col Ther, 1992 ; 52: 335-41
43 Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC .Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tu- berculosis in mice[ J] . Am Rev Respir Dis, 1993; 148: 1541-6
44 Centers for Disease Control . US Department of Health and Hu- man Service. Diagonsis and management of mycobacterial infec- tion and disease in persons with human immunodeficiency virus- infection[ J] . Ann Intern Med, 1987; 106 : 254-6
45 Obrien RJ, Lyle MA, nider Jr DE.Rifabutin ( Ansamy cin LM127) : A new rifamycin-Sderivative for the treatment of myco- bacterial disease[ J] .Rev Infect Dis, 1987; 9: 519 -30 中国临床药理学与治疗学 2006 Jan; 11( 1) · 7 ·46 HongKong Chest service British Medical Research Council .A controlled study of rifabutin and an uncontrolled study of oflxacin in the treatment of patients with pulmonary tuberculosis resistant to isonaizid . streptomycin and rifampicin[ J] .Tubercle Lung Disease, 1992 ; 73: 60-8
47 Felten HK.Preliminary experience with rifabutin ( Ansamycin LM427) in patients with diagnosed pulmonary tuberculosis ( PTB) and chronic disease[ J] .Am Rev Respir Dis, 1987 ; 135 : At36
48 Canetti G. The tubercle bacillus in the pulmonary lesions of man [ M] . New York: Springer, 1955: pp62-8
49 Bates JH .Transmisson .pathogenesis.pathology and clinical manisfestations of tuberculosis.In Kubika G P.Wayner L G . eds.The mycobacterial[ J] .A sourcebook Part B .New York : Mareel Dekker, 1984: p997
50 L J, Gonzalez-Montaner S, Natal P, Yongchaiyud, P Olliaro, et al .用 Rifabutin 治疗近期诊断的肺结核:该药对利福平的多国随机比较性研究[ J] .结核与肺部疾病杂志中文版, 1996; 3 : 99-106
51 Lee J, O' Morain C.Consensus or confusion : a review of existing national guidelines on Helicobacter pylori related disease[ J] . Eur J Gastronenterol Hepatol, 1997; 9 : 527-31
52 The European Helicobacter pylori Study Group. Current Europe- an concepts in the mangement of Helicobacter pylori infection [ J] .Maastricht Consensus Report Gut, 1997 ; 41: 8-13
53 Xia HX, Buckley M, Keane CTClarithromycin resistance in He- licobacter pylori : prevalence in untreated dyspeptic patients and stability in vitro[ J] . J Antimicrob Ther, 1996; 37: 473 -81
54 Adamek RJ, Suerbaum S, Pfaffenbach B. Primary and acquired Helicobacter pylori resistance to clarithromycin[ J] .Outcome Am J Gastroenterol, 1998 ; 93: 386-9
55 Megraud F, Occhialini A, Doermann HP.Resistance of Helico- bacter pylori to macrolides and nitroimidazole compounds . The current situation[ J] . J Physiol Pharmacol, 1997 ; 48: 25-38
56 Brogden RN, Fitton A, Rifabtuin.A review of its antimicrobial activity pharmacokinetic properties and therapeutic efficacy[ J] . Drugs, 1994 ; 47: 983-1009
57 Rossl R, Jabes D, Della Bruna C .In vitro activity of rifabutin, a potential antibiotic in the therapy of Helicobacter pylori .In : abstract book of the 6th international congress for infectious dis- ease( ICID) prague[ R] .Czech Republic, 1994; 69
58 Unghert D, Della Bruna C, Jabes D. LM 427: Further studies on the antimycobacterial activity[ R] . In Proceedings of the 13th In- ternational Congress of Chemotherapy ( ICC ) .Wien.Austria, 1983
59 Heep M, Beck D, Bayerdorffer E, Lehn N.Rifampin and rifabu- tin resistance mechanism in Helicobacter pylori[ J] . Antimicrob Agents Chemother, 1999; 43: 1497 -9
60 Strolin Beneditti M, Dostert P. Induction and autoinduction prop- ertities of rifamycin derivatives: a review of animal and human studies[ J] . Environ Health Perspect, 1994 ; 102; 101-5
61 Maurel P. The CYP3A family[ A] . In Cytochrome P450 : meta- bolic and toxicological aspect[ M] . CRC Press, 1995
62 Mautel P. The use of adult human hepatocytesin primary culture and other in vitro systems to investigate drug metabolism in man [ J] . Adv Drug Delivery Rev, 1995; in press
63 Oesch F, Arand M, Strolin Beneditti M, Dostert P, Castelli MG. Inducing properties of rifabutin and rifampicin for selected drug metabolizing enzymes in female rat liver[ R] . Ixth International Conference on AIDS, Berlin, 6-11 June 1993.Abstract Book , Vol .1, 328, No. PO-BO7-1155
64 Burchell B, Nebert DW, Nelson DR, Bock KW, Iyanagi T, Jans- en PLM, et al . The UDP glucuronosyltransferse based on evolu- tionary divergence[ J] . DNA cell Biol, 1991; 10: 487 -94
65 Price Evans DA.Genetic factors in drug therapy[ A] .Clinical and molecular pharmcogenetics[ M] .Cambridge University Press, 1993; 306-29
66 Ged C, Rouilion JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel . H , et al .The increase in urinary excretion of 6-β- hydroxycortisol as a marker of human hepatic cytochrome P4- 50IIIA induction[ J] . Br J Clin Pharmacol, 1989 ; 28: 373-87
67 Perucca E, Grimaldi R, Frigo GM, Sardi A, Monig H, Ohnhaus EE . Comparative effects of rifabutin and rifapicin on hepatic mi- crosomal enzyme activity in normal subjects[ J] .Eur J Clin Pharmacol, 1988; 34: 595 -9
68 Zilly W, Breimer DD, Richter E. Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance[ J] .Eur J Clin Pharmacol, 1977; 11: 287 -93
69 Breda M, Pianezzola E, Stronlin Benedetti M, Efthymiopoulous C, Carpentieri M, Sassella D, et al . A study of the effects of ri- fabutin on isoniazid pharmacokinetics and metabolism in healthy volunteers[ J] . Drug Metab Drug Interact, 1992; 10 : 323-40
70 Strolin Benedetti M, Breda M, Pellizzoni C, Poggesi I, Sassella D, Dolfi L, Rimoldi R. Effect of rifabutin on ethambutol pharma- cokineticsin healthy volunteers[ R] . First Congress and Thera- peutics, Paris, 27-30 September 1995 . Book of Abstracts
71 Strolin Benedetti M. Inducing properties of rifabutin and effects on the pharmacokinetics and metabolism of concomitant drugs [ J] . Pharmacological Research, 1995 ; 32: 4
72 Strolin Benedetti M, Duchene P, Olliaro P. Investigation on a possible induction of AZT glucuronidation by rifabutin and ri- fampicin in humans[ R] . Proceedings of the Third International ISSX Meeting , Amsterdam, 24-28 June 1991 .Book of Ab- stracts, p . 295
73 Sahai J, Foss N, Li R, Narang PK, Cameron DW.Rifabutin( R) and didanosine( ddi) interaction in AIDS patients[ J] . Clin Phar- macol Ther, 1993; 53: 197
74 Borin MT, Cox SR, Driver MR, Freimuth WW, Aksentijevich S, Piergies AA.Effect of rifabutin ( RFB) on delavirdine ( DLV) pharmacokinetics in HIV ( +) patients[ R] .34thInterscience Conference on Antimicrobial Agents and Chemotherapy, Orlan- do. 4-7
75 Borin MT, Cox SR, Chambers JH, Freimuth WW, Gagon S .Ef- fects of rifampin( RIF) on delavirdine ( DLV) pharmacokinetics inHIV( +) patients[ R] . 34th Interscience Conference on Anti- microbial Agents and Chemtherapy . Orlando, 4-7 October1994. Book of Abstracts . P. 82. No. A50
76 Voorman RL, Maoi SM, Wang X.Mechanism-based inactivation of rat and human cytochrome P450 3A by delavirdine[ R] . 9th · 8 · Chin J Clin Pharmacol Ther 2006 Jan; 11( 1)International Conference on Cytochrome P450 .Biochemistry , Biophysics and Molecular Biology . Zurich .23-27 July 1995 . Book of Abstracts, p. 252 . no. Pmec-21
77 Trapnell CB, Lavelle JP, Oleary CR, James DS, Li R, Colburn D, et al .Rifabutin does not alter fluconazole pharmacokinetics [ J] . Clin Pharmacol Ther, 1993 ; 53: 196
78 Smith JA, Hardin TC, Patterson TF, Rinaldi MG, Graybill JR. Rifabutin( RIF) decreases itraconazole ( ITRA) plasma levels in patients with HIV-infection[ R] .2nd National Conference on Human Retroviruses and Related Infections .Washington, 29 January-2 February 1995 . Book of Abstracts, p. 77, no . 126
79 Sawyer RC, Brown LS, Narang PK, Li R.Evaluation of a possi- ble pharmacologic interaction between rifabutin( RIF) and meth- adone( MET) in HIV( +) injecting drug users( IDUs)[ R] . Ixth International Conference on AIDS, Berlin. 6-11 June 1993. Ab- stract Book , Vol. 1, p. 501, no. PO-B30-2197
80 Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Re- duced serum levelsof clarithromycin in patients on multidrug reg- imens including rifampin or rifabutin for treatment of mycobacte- rium avium-intramicrobial[ J] . Agents and Chemotherapy, Orlan- do, 4-7 October 1994. Book of Abstracts, p . 246, no. M59
81 Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Re- duced serum levelsof clarithromycin in patients treated with mul- tidrug regimens including rifampin or rifabutin for treatment of mycobacterium avium-intramicrobial infection[ J] . J Inf Dis , 1995 ; 171: 747-50
82 Datri 001 Study group;Clarithromycin( CL) plus rifabutin( RFB) for MACprophylaxis: evidence for a drug interaction[ R] . 1st Na- tional Conference on Human Retroviruses and Related Infections , Washington , DC . December 12-16, 1993.Book of Abstracts . p . 106. no. 299
83 Gillum JG, Sesler JM, Bruzzese VL, Israel DS, Polk RE.Com- parison of rifampin ( RIF) and rifabutin ( RFB) volunteers[ J] . 34th Interscience Conference on Antimicrobial Agents and Che- motherapy . Orlando . 4-7 October 1994.Book of Abstacts , p. 7. no. A1
84 Vandvelde C, Chang A, Andrews D, Riggs W, Jewesson P.Ri- fampin and ansamycin interaction with cyclosporine after renal transplantation[ J] . Pharmacotherapy , 1991; 11: 88 -9
85 scher DP, affers GJ, avis SG . Rifabutin hepatotoxicity in a pedi- atric liver transplant patient[ J] . Pharm Technol, 1994; 10: 258 -60
86 Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, et al .对香港肺结核病人做痰液活菌计数测定以评价利福布丁的早期杀菌作用[ J] .结核与肺部疾病杂志中文版, 1995; 1 : 107-12

[1]	LU Kepeng, LIU Caihong, BI Ying. Effect of prophylactic anticoagulation duration on venous thrombosis after total hip/knee arthroplasty [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1269-1274.
[2]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[3]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[4]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[5]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[6]	JIANG Daoli, CHOU Xiaohua, LIU Zhidong, LI Wei, ZHANG Bo, XU Sang, TAN Defei, FANG Yi, LV Dongmei, WANG Tao. Real-world study of ceftazidime-avibactam in the treatment of multidrug-resistant gram-negative bacterial infections [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1008-1017.
[7]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[8]	WANG Fei, HANG Yongfu, WANG Wei. Influence of argumented renal clearance on teicoplannin serum concentrations in critical ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1043-1048.
[9]	HUA Zhihui, LIU Dong, ZHANG Jiandong, CAI Siyu, GE Chunli, CHEN Nan, QI Qi. Clinical evaluation of the efficacy against helicobacter pylori by amoxicillin from volume-based procurement and potassium amoxicillin clavulanate [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1061-1066.
[10]	ZHONG Wei, SHI Shuxia, QIN Qinyue, YU Guo. Measurement tools and rationality evaluation of clinical research coordinator's work ability and workload [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 937-947.
[11]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HE Qing, HUANG Kai. Analysis of reasons for screening failure of healthy subjects in clinical trials of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 758-766.
[12]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[13]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[14]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[15]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.